TXG News and Press, 10x Genomics Inc. From 08/02/22

This year, two major catalysts for SoftBank are the potential sale of the Fortress Investments subsidiary and the Arm IPO. This complicated company has faced underperformance over the past few years, especially after the 2020 speculation boom. However, if valuation reaches a certa...

TXG is a life sciences company trading at 8x P/S and 4.9x P/B (after experiencing multiple compression from a P/S of 58x and a P/B of 23x). The company has never been profitable and expects to incur losses in the future. Insiders have been consistently selling heavily over the pas...

Cytek and 10x Genomics both offer single cell visualization tools, a growing and important field in modern medicine. However, each company sees huge differences in popularity, financial performance, and valuation, leading to a significant difference in outlook. This article will c...

Company announces actions to lower near-term cash burn. Revenue growth targets come in well below expectations. Stock could easily re-test its 2022 low. Back in March, I detailed how genetics company Invitae ( NVTA ) could massively dilute investors in the coming mon...

Stocks finished higher on Friday, bouncing back after a downdraft that dominated most of the past several days. The gains came amid renewed confidence that the Federal Reserve would stick with the expected 75-basis-point rate hike at its next policy meeting, rather than resorting to a full-...

Gainers: Vertical Aerospace ( EVTL ) +31% . NexImmune ( NEXI ) +31% . 180 Life Sciences ( ATNF ) +21% . ToughBuilt Industries ( TBLT ) +20% . Energy Vault Holdings ( NRGV ) +17% . EyePoint Pharmaceuticals ( EYPT ) +...

Gainers: NexImmune ( NEXI ) +34% . Allogene Therapeutics ALLO +12% . SOPHiA GENETICS ( SOPH ) +12% . Verona Pharma ( VRNA ) +8% . R1 RCM ( RCM ) +7% . Losers: Codexis ( CDXS ) -43% . 10x Genomics ( TXG ...

Codexis ( CDXS ) -23% as forecast comes below estimates . 10x Genomics ( TXG ) -19% on guiding Q2 revenues below consensus . Innovative Industrial Properties ( IIPR ) -21% . Lantern Pharma ( LTRN ) -10% . Sunrun ( RUN ) -8%...

Steadily growing, highly free-cash-flow-generative and more moderately valued companies enabled the Strategy to outperform through a sharp market pullback. Heightened volatility provided opportunities to purchase shares in growth companies on our watchlist, as well as add to existing ...

ARK Invest’s 13F portfolio value decreased from $23.96B to $16.91B this quarter. Coinbase Global, Roku, Shopify, and Ginkgo Bioworks were increased while decreasing Spotify, Ionis Pharma, Vertex Pharma, and Sea Limited. The top three positions are Tesla, Zoom Video, and Rok...